• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 8, 2011

View Archived Issues

Optimer's C. Diff Drug Lures Regional Astellas Partnership

Worries that generic vancomycin could cut into the market potential for Optimer Pharmaceuticals Inc.'s Clostridium difficile infection (CDI) drug fidaxomicin have been eased somewhat, with Astellas Pharma Europe Ltd. jumping on board in a potential $224 million regional deal. Read More

Study Shows Balance Between Brain Regions Key to Dystonia

Dystonias "are the third most common movement disorder in the world," Kamran Khodakhah told BioWorld Today. But for all that, neither their causes nor possible cures are particularly well worked out. Read More

Do Biotechs Really Have the Upper Hand in Pharma Deals?

It has become common wisdom that, in the face of patent expirations and sparse pipelines at major pharma companies, biotechs are in a strong position to negotiate advantageous deal terms – and not just companies with late-stage assets, but a whole spectrum of the industry. Sounds like good times ahead. But as 2011 gets under way, it's not so clear that the industry has the upper hand in its dealings with big pharma, nor that these large companies are necessarily looking first to the biotech industry to solve their problems. Read More

Corrections & Clarifications

An article in BioWorld Today, Feb. 7, 2011, on Endocyte Inc. should have reported a "p" value of 0.031 from the PRECEDENT study of EC145 in ovarian cancer. Read More

Financings Roundup

RedHill Biopharma Ltd., of Tel Aviv, Israel, completed its initial public offering (IPO) for listing on the Tel Aviv Stock Exchange. The company raised NIS51.6 million (US$13.6 million), with proceeds to support development of RedHill's six late-stage programs, including its experimental treatment of MAP infection in Crohn's disease. RedHill, which focuses on acquiring and developing late-stage, new formulations of existing drugs, initially had planned to raise NIS40 million, but strong demand at the IPO prompted the firm to increase its offering at a price 18.3 percent higher than planned. The company sold 131,000 units – each comprising 100 shares and 50 warrants – with a minimum unit price of NIS305. Read More

Stock Movers

Read More

Clinic Roundup

Human Genome Sciences Inc., of Rockville, Md., and GlaxoSmithKline plc, of London, said data from the pivotal BLISS-52 study of Benlysta (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus was published in The Lancet. Data from that study, the first of two positive pivotal trials, originally were reported in 2009. Read More

Other News To Note

Inovio Pharmaceuticals Inc., of Blue Bell, Pa., announced that its DNA vaccine delivery technology, which provides the enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in Human Vaccines. Read More

Appointments and Advancements

4-Antibody AG, of Basel, Switzerland, appointed Robert F. Burns CEO. Read More

Progenics Picks Salix Sales of Relistor in Potential $350M Deal

If at first you don't succeed . . . Progenics Pharmaceuticals Inc. licensed rights to Relistor (methylnaltrexone bromide), its opioid-induced constipation (OIC) drug for patients with advanced disease, to Salix Pharmaceuticals Ltd. in a deal potentially worth $350 million or more. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe